Diferencia entre revisiones de «SGLT-2 Inhibitor»
Sin resumen de edición |
|||
| Línea 23: | Línea 23: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Endocrinology]] | |||
Revisión del 22:22 23 sep 2019
Administration
- Type: Oral Diabetes medication
- Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- UTI
- Genital candidiasis
- Weight loss
- Dehydration/Orthostasis
Mechanism of Action
- Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule